ScholarIQanswers from OpenAlex
South Texas Accelerated Research Therapeutics
InstitutionResearch output, impact & collaborations
South Texas Accelerated Research Therapeutics is a institution indexed in ScholarIQ from OpenAlex.
What is known about South Texas Accelerated Research Therapeutics?
ScholarIQrecord summary
South Texas Accelerated Research Therapeutics is a research organisation in San Antonio, US. OpenAlex records 1,533 works and 119,176 citations for it. 224 researchers list it as their most recent affiliation.
How many works does South Texas Accelerated Research Therapeutics have?
ScholarIQindexed works
South Texas Accelerated Research Therapeutics has 1,533 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does South Texas Accelerated Research Therapeutics have?
ScholarIQcitation count
South Texas Accelerated Research Therapeutics has 119,176 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at South Texas Accelerated Research Therapeutics?
ScholarIQresearcher count
South Texas Accelerated Research Therapeutics has 224 researchers in the ScholarIQ index.
What is the average h-index at South Texas Accelerated Research Therapeutics?
ScholarIQavg h-index
South Texas Accelerated Research Therapeutics has an average h-index of 71 in OpenAlex.
What is the ROR of South Texas Accelerated Research Therapeutics?
ScholarIQror
The ROR for South Texas Accelerated Research Therapeutics is on the source record.
What is the OpenAlex record for South Texas Accelerated Research Therapeutics?
ScholarIQopenalex
The OpenAlex for South Texas Accelerated Research Therapeutics is on the source record.
Who are the most-cited researchers behind South Texas Accelerated Research Therapeutics?
ScholarIQtop researchers by citations
What are the most-cited papers on South Texas Accelerated Research Therapeutics?
ScholarIQmost cited works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, John Hilton, Aejaz Nasir, Richard P. Beckmann, Andrew E. Schade, Angie D. Fulford, Tuan S. Nguyen, Ricardo Martínez, Palaniappan Kulanthaivel, Lily Q. Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro
Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Anthony W. Tolcher, Wells A. Messersmith, Stanislaw M. Mikulski, Kyriakos P. Papadopoulos, Eunice L. Kwak, Darlene Gibbon, Amita Patnaik, Gerald S. Falchook, Arvind Dasari, Geoffrey I. Shapiro, John F. Boylan, Zhi-Xin Xu, Ka Wang, Astrid Koehler, James Song, Steven A. Middleton, Jonathan Deutsch, Mark DeMario, Razelle Kurzrock, Jennifer J. Wheler
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Glen J. Weiss, Jasgit C. Sachdev, Manpreet Chadha, Maddie Fulk, Samuel Ejadi, James M. Mountz, Michael T. Lotze, Frederico G. S. Toledo, Edward Chu, Michael Jeffers, Carol E. Peña, Chenjing Xia, Stefanie Reif, Isabelle Genvresse, Ramesh K. Ramanathan
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny Amore, Dirk Nagorsen, John S. Hill, Joe Stephenson
Who collaborates most closely around South Texas Accelerated Research Therapeutics?
ScholarIQco-authorship network
United States
100%
MOST FREQUENT PARTNER INSTITUTIONS
How much of the research on South Texas Accelerated Research Therapeutics is open access?
ScholarIQopen access share
86%OPEN ACCESS